Seminars in Oncology
Volume 34, Issue 6 , Pages 449-451 , December 2007

Melanoma 2007: Current State and Preview of the Future

References 

  1. Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature. 2007;445:843–850
  2. Miyamura Y, Coelho SG, Wolber R, et al. Regulation of human skin pigmentation and responses to ultraviolet radiation. Pigment Cell Res. 2007;20:2–13
  3. D’Orazio JA, Nobuhisa T, Cui R, et al. Topical drug rescue strategy and skin protection based on the role of MC1r in UV-induced tanning. Nature. 2006;443:340–344
  4. Mooi WJ, Peeper DS. Oncogene-induced cell senescence—Halting on the road to cancer. N Engl J Med. 2006;355:1037–1046
  5. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: A systematic review and meta-analysis. Can J Surg. 2003;46:419–426
  6. Riker AI, Glass F, Perez I, et al. Cutaneous melanoma: Methods of biopsy and definitive surgical excision. Dermatol Ther. 2005;18:387–393
  7. Blazer DG, Sondak VK, Sabel MS. Surgical therapy of cutaneous melanoma. Semin Oncol. 2007;34:270–280
  8. Clark WH, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–726
  9. Morton DL, Eilber FR, Malmgren RA, et al. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970;68:158–164
  10. Hersh EM, Gutterman JV, Mavligit GM. BCG as adjuvant immunotherapy for neoplasia. Ann Rev Med. 1977;28:489–515
  11. Veronesi V, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307:913–916
  12. Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17:201–209
  13. Shiku H, Takahashi T, Oettgen HF. Cell surface antigens of human malignant melanoma (II. Serological typing with immune adherence assays and definition of two new surface antigens). J Exp Med. 1976;144:873–881
  14. Dippold WG, Lloyd KO, Li LT, et al. Cell surface antigens of human malignant melanoma: Definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA. 1980;77:6114–6118
  15. Krown SE, Burk MW, Kirkwood JM, et al. Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society phase II trial. Cancer Treat Rep. 1984;68:723–726
  16. Rosenberg SA, Mule JJ, Spiess PI, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161:1169–1188
  17. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology group Trial EST 1684. J Clin Oncol. 1996;14:1–17
  18. Wang W, Edington HD, Rao UN, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007;13:1523–1531
  19. Borden EC. Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: Potential application to melanoma. Cytokine Growth Factor Rev. 2007;18:491–501
  20. Peggs KS, Quezada SA, Kormann AJ, et al. Principles and use of an anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18:206–213
  21. Liu L, Gerson SL. Targeted modulation of MGMT: Clinical implications. Clin Cancer Res. 2006;12:328–331
  22. Bae SI, Cheriyath V, Jacobs BS, et al. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene [Epub ahead of print]. 2007;

 Research related to melanoma supported in part by NIH R01CA90914 and M01 RR-018390.

PII: S0093-7754(07)00176-5

doi: 10.1053/j.seminoncol.2007.09.001

Seminars in Oncology
Volume 34, Issue 6 , Pages 449-451 , December 2007

Article Tools